BLFS – the most advanced company for biopreservation media products!
Zacks small cap research - Demand for biopreservation media is estimated to grow at an
annual rate of almost 20% over the next several years,
largely driven by rapid growth of the emerging field of
regenerative medicine (including cell therapy and tissue
engineering). BioLife's strategy is to build greater visibility
and awareness of the benefits of their biopreservation
products compared to the "home-brews" that currently
dominate the market. Meanwhile, the company's contract
manufacturing business, which is expected to generate
~$2.4MM in revenue in 2012 as a result of the signing if a key
customer during 2011, is expected to provide a source of
near-term revenue and cash flow to help fund the further
development and commercialization of the biopreservation
media business, which is expected to provide the bulk of
revenue and drive earnings for the long-term. Moving our
price target from $0.50 to $0.70.
Sentiment: Buy